|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.05.26 - 13:06
|
Insulet Reports First Quarter 2026 Results (Business Wire)
|
|
|
Raises Full Year Total Company Revenue GuidanceACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026.
First Quarter Financial Highlights:
Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company's guidance range of 25% - 27% at constant currency rates
Total Omnipod revenue of $758.4 million, rose 36.9%, or 33.0% in constant currency
U.S. Omnipod revenue of $515.6 million, increased 28.3%
International Omnipod revenue of $242.9 million, increased 59.4%, or 45.2% in constant currency
Drug Delivery revenue of $3.3 million
Operating income of $122.1 million, or 16.0% of revenue, up 40 basis points over prior year
Adjusted operating income1 of $133.5 million, or 17.5% of revenue, up 110 basis points over prior year
Net income of $91.1 million, or $1.3...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.04.26 - 13:03
|
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026 (Business Wire)
|
|
|
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers; the passcode is 5904836.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its...
|
|
|
30.03.26 - 14:36
|
Insulet Appoints Mike Panos as Chief Commercial Officer (Business Wire)
|
|
|
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet's global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team.
“We have a significant growth opportunity in front of us, driven by strong clinical outcomes, customer-centric innovation, and expanding global adoption of automated insulin delivery as the standard of care in both type 1 and type 2 diabetes,” said Ashley McEvoy, Insulet President and Chief Executive Officer. “We are implementing thoughtful strategies to strengthen our capabilities and structure to capture this opportunity and are thrilled to welcome Mike to Insulet. His expertise in bui...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
